Assessment of blood interactions with the Therapore Apheresis System.
Biocompatibility evaluations are a complex issue involving not only classical toxicity and animal testing but also the interactions of biological systems. The evaluations of the Therapore Primary System are reported for three model systems: (1) in vitro human blood, (2) a baboon (Papio anubis) animal model, and (3) normal human volunteer apheresis. Measurements of both complement (C3a) and platelet (BTG and TXB2) activation products during the apheresis procedures are given as a sensitive indicator of biocompatibility. No statistically significant elevations of these activation products were observed. Thus, the Therapore System was found to have negligible perturbations of the interacting biological systems evaluated even with the highly sensitive RIA procedures employed. These observations and methods establish a solid foundation for comprehensive biocompatibility evaluations of future extracorporeal devices.
D000818:Animals; D001672:Biocompatible Materials; D001769:Blood; D003167:Complement Activation; D003176:Complement C3 / Q000032:analysis; D015926:Complement C3a; D006452:Hemoglobinometry; D006801:Humans; D010215:Papio; D010956:Plasmapheresis / Q000009:adverse effects / Q000295:instrumentation*; D011863:Radioimmunoassay; D013929:Thromboxane B2 / Q000032:analysis; D001620:beta-Thromboglobulin / Q000032:analysis
D001672:Biocompatible Materials; D003176:Complement C3; D001620:beta-Thromboglobulin; D013929:Thromboxane B2; D015926:Complement C3a